包头东宝生物技术股份有限公司 第八届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 | 证券代码:300239 | | --- | | 债券代码:123214 | 证券代码：300239 证券简称：东宝生物 公告编号：2023-085 债券代码：123214 债券简称：东宝转债 6、本次会议的召集、召开和表决程序符合法律、行政法规、部门规章、规 范性文件和《公司章程》的有关规定，合法有效。 二、监事会会议审议情况 与会监事认真审阅了有关议案并进行了表决。经与会监事一致同意，形成决 议如下： 审议通过了《关于修订<监事会议事规则>的议案》 公司根据监管部门法律法规，结合公司实际情况，对《监事会议事规则》进 行了修订。公司监事会同意本次修订内容，并同意提交公司股东大会审议。 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届监事会第十 八次会议通知于 2023 年 12 月 8 日以直接送达或电子邮件等方式通知了全体监事 及董事会秘书。 2、会议召开时间、地点及方式：会议于 2023 年 12 月 11 日 ...

包头东宝生物技术股份有限公司 投资者关系管理制度 (2023 年 12 月) 第一章 总则 第一条 为加强包头东宝生物技术股份有限公司（以下简称"公司"）与投 资者和潜在投资者（以下统称"投资者"）之间的信息沟通，加深投资者对公司 的了解与认同，促进公司与投资者之间形成长期、稳定的良性关系，促进公司诚 信自律、规范运作，并进一步完善公司治理结构，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司投资者关系管理工作指引》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《规范运作》"）、《包头东宝生物技术股份有限公司章程》（以 下简称《公司章程》）及其他相关法律、法规和规定，结合公司的实际情况，制 定本制度。 第二条 公司投资者关系管理工作应严格遵守《公司法》、《证券法》等有 关法律、法规、规章及深圳证券交易所有关业务规则的规定。 第三条 公司投资者关系管理工作应遵循公平、公正、公开原则，平等对待 全体投资者，保障所有投资者享有知情权及其他合法权益。 第四条 公司的投资者关 ...

第二条 本制度所称"信息"是指可能对公司证券及其衍生品种交易价格 产生较大影响而投资者尚未得知的重大信息，以及中国证监会及其派出机构、深 圳证券交易所要求披露的信息；本制度所称"披露"是指在规定的时间内、在指 定的媒体上、以规定的方式向社会公众公布前述信息，并按规定报送证券监管部 门。 包头东宝生物技术股份有限公司 信息披露事务管理制度 (2023 年 12 月) 第一章 总则 第一条 为规范包头东宝生物技术股份有限公司（以下简称"公司"）信息 披露行为，促进公司依法规范运作，确保公司信息披露的真实、准确、完整与及 时，切实维护公司股东、债权人及其利益相关人的合法权益，依据《中华人民共 和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司信息披露管理办法》、《上市公司治理准则》等规定 及《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳 证券交易所上市公司自律监管指引第 5 号——信息披露事务管理》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《包头东 宝生物技术股份有限公司章程》（以下简称《公司章程》）的有关规定 ...

Financial Performance - The company's revenue for Q3 2023 was ¥213,972,459.55, a decrease of 6.84% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2023 was ¥30,257,596.62, an increase of 1.50% year-on-year[6]. - For the first three quarters of 2023, the company achieved operating revenue of RMB 734,671,103.09, representing a year-on-year increase of 4.05%[22]. - The net profit attributable to shareholders of the listed company was RMB 95,261,690.05, reflecting a year-on-year growth of 8.52%[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 89,766,473.80, with a year-on-year increase of 8.05%[22]. - The company's net profit attributable to shareholders increased to CNY 331,352,738.98 from CNY 251,524,726.48, reflecting a growth of about 31.7%[28]. - The net profit for the third quarter of 2023 was CNY 101,932,609.79, an increase of 10.3% compared to CNY 92,439,092.18 in the same period last year[31]. - The total profit for the quarter was CNY 119,002,673.77, up from CNY 107,878,453.53, which is an increase of 10.4%[31]. Assets and Liabilities - The total assets at the end of Q3 2023 reached ¥2,713,125,525.40, reflecting a growth of 17.55% compared to the end of the previous year[6]. - As of September 30, 2023, the total assets of Baotou Dongbao Biotechnology Co., Ltd. reached CNY 2,713,125,525.40, an increase from CNY 2,308,113,622.60 at the beginning of the year[26]. - The company's total current assets increased to CNY 1,363,079,739.40 from CNY 1,023,890,791.80, reflecting a growth of approximately 33.2%[26]. - The total liabilities rose to CNY 838,743,897.90, compared to CNY 552,258,173.95 at the start of the year, indicating a significant increase of about 51.9%[27]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥130,287,710.94, an increase of 2.81%[6]. - The net cash flow from operating activities was CNY 130,287,710.94, compared to CNY 126,730,842.75 in the previous year, indicating a slight increase of 4.0%[32]. - The company reported a net cash inflow from financing activities of CNY 320,156,942.98, significantly higher than CNY 127,868,845.94 in the same quarter last year, marking an increase of 150.2%[33]. - The total cash and cash equivalents at the end of the period reached CNY 712,939,787.40, up from CNY 284,292,166.88, showing a growth of 150.1%[33]. Shareholder Information - The top shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of the shares, amounting to 125,711,022 shares, with 88,000,000 shares pledged[18]. - The total number of common stock shareholders at the end of the reporting period was 25,259[17]. - The company has a total of 79,520,464 restricted shares, with 1,476,169 shares released during the period[21]. Investment and Projects - The company issued convertible bonds during the reporting period, resulting in a significant increase in cash flow from financing activities by 150.38% to ¥320,156,942.98[16]. - The company plans to issue 4,550,000 convertible bonds at a face value of RMB 100 each, raising a total of RMB 455,000,000[24]. - The actual net amount raised from the bond issuance, after deducting related expenses, is RMB 442,263,443.42[24]. - The construction in progress increased by 77.62% to ¥284,718,051.61, attributed to investments in a new intelligent capsule project[11]. Operating Costs and Expenses - The total operating costs increased to CNY 618,064,708.07 from CNY 603,614,933.33, which is an increase of about 2.4%[29]. - Research and development expenses for the period were CNY 19,739,946.75, compared to CNY 17,057,544.09 in the previous period, marking an increase of approximately 15.7%[29]. Other Financial Metrics - The company's basic earnings per share for Q3 2023 was ¥0.0510, up by 1.59% from the previous year[6]. - Basic and diluted earnings per share increased to CNY 0.1605 from CNY 0.1479, representing a rise of 17.0%[32]. - The company recorded a net investment loss of ¥3,647,909.07, which was 407.39% higher than the previous period, primarily due to higher losses from long-term equity investments[13]. - The company incurred a credit impairment loss of CNY 510,785.46, while the asset impairment loss was CNY 19,226.86, indicating challenges in asset management[31].

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2023-083 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 公司于 2020 年 11 月 24 日披露了《2020 年向特定对象发行股票募集说明书 (注册稿)》，经中国证券监督管理委员会《关于同意包头东宝生物技术股份有限 公司向特定对象发行股票注册的批复》(证监许可〔2020〕3058 号)同意注册，向 特定对象发行股票人民币普通股(A 股)72,728,875 股，发行价格为 5.60 元/股，实 际募集资金总额为人民币 407,281,700.00 元，扣除与发行有关的费用人民币 10,588,219.76 元(不含税)，实际募集资金净额为人民币 396,693,480.24 元，用于 实施生态资源综合利用建设项目等募集资金投资项目以及补充流动资金。大华会 计师事务所(特殊普通合伙)已于 2021 年 5 月 26 日对公司向特定对象发行股票的 资金到位情况进行了审验，并出具了《验资报告》(大华验字[2021]000351 号)， 确认募集资金到账 ...

| 证券代码:300239 | | --- | | 债券代码:123214 | 证券代码：300239 证券简称：东宝生物 公告编号：2023-080 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 第八届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届监事会第十七次 会议通知于 2023 年 10 月 24 日以直接送达或电子邮件等方式通知了全体监事及 董事会秘书。 2、会议召开时间、地点及方式：会议于 2023 年 10 月 27 日(星期五)上午 11:30 在公司会议室以现场与通讯结合方式召开。 3、会议出席人员：本次会议应出席监事 3 名，实际出席监事 3 名(其中通讯 出席监事 1 名、现场出席监事 2 名)，监事会主席周兴先生以通讯方式出席会议， 监事于建华先生、杜学文先生出席现场会议。 4、会议列席人员：副总经理兼董事会秘书单华夷女士。 5、本次会议由监事会主席周兴先生主持。 6、本次会议的召集、召开和表决程序符 ...

| 证券代码:300239 | | --- | | 债券代码:123214 | 证券代码：300239 证券简称：东宝生物 公告编号：2023-079 债券代码：123214 债券简称：东宝转债 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届董事会第十七次 会议通知于 2023 年 10 月 24 日以直接送达或电子邮件等方式通知了全体董事、 监事、高级管理人员。 2、会议召开时间、地点及方式：会议于 2023 年 10 月 27 日(星期五)上午 10:30 在包头稀土高新区包头东宝生物技术股份有限公司会议室以现场与通讯方式结 合召开。 3、会议出席人员：本次会议应出席董事 7 名，实际出席董事 7 名(其中，现 场出席 5 名，通讯出席 2 名)。董事长王爱国先生、董事兼副总经理刘燕女士以 通讯方式出席了本次会议，董事兼总经理刘芳先生、董事兼副总经理王富荣先生、 独立董事高德步先生、任斌先生、额尔敦陶克涛先生出席了现场会议。 4、会议列席人员：公司监事会主席周兴先生以通讯方式 ...

招商证券股份有限公司 关于包头东宝生物技术股份有限公司 部分募集资金投资项目延长实施期限的核查意见 招商证券股份有限公司（以下简称"招商证券"、"保荐机构"）作为包头东 宝生物技术股份有限公司（以下简称"东宝生物"、"公司"）持续督导的保荐机 构，根据《证券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》、《深圳证券交易所创业板股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等相关法律、法规及规范性文件，对东宝生物部分募集资金投资项目延长实 施期限的事项进行了核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意包头东宝生物技术股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2020〕3058号）同意，公司向 特定对象发行股票人民币普通股(A股)72,728,875股，发行价格为5.60元/股，实 际募集资金总额为人民币407,281,700.00元，扣除与发行有关的费用人民币 10,588,219.76元(不含税)，实际募集资金净额为人民币396,693,480.24元，用 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[20]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[20]. - The company's operating revenue for the first half of 2023 was ¥520,698,643.54, representing a 9.31% increase compared to ¥476,359,062.02 in the same period last year[26]. - Net profit attributable to shareholders was ¥65,004,093.43, up 12.12% from ¥57,974,911.31 year-on-year[26]. - The total profit reached ¥81,917,126.55, an increase of 13.13% compared to the previous year[56]. - The net cash flow from operating activities decreased significantly by 84.45%, amounting to ¥16,834,764.92 compared to ¥108,230,931.16 in the previous year[26]. - Basic and diluted earnings per share increased by 12.08% to ¥0.1095 from ¥0.0977[26]. - The company reported a significant decrease in financial expenses by 99.25%, primarily due to reduced borrowing costs and increased interest income[79]. - The company achieved a profit from asset disposal of ¥28,498.05, which is a 54.99% increase compared to the previous year[80]. Production Capacity and Expansion - The company plans to expand its production capacity from 3,500 tons to 7,000 tons for its gelatin products by the end of 2023[20]. - The company has an annual production capacity of 13,500 tons of gelatin and 24 billion capsules, positioning it as a leader in the industry[46]. - The new intelligent industrialization projects for hollow capsules will increase production capacity to nearly 70 billion capsules annually[46]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[20]. - The company is actively addressing management risks associated with its expanding operational scale by optimizing governance and enhancing risk management awareness[117]. - The company is expanding its production capacity for hollow capsules to meet the increasing market demand, as the current capacity is insufficient[109]. Research and Development - The R&D investment for new product development increased by 25% year-on-year, focusing on collagen products and health supplements[20]. - The company's R&D investment decreased by 6.46% to ¥18,935,938.36 from ¥20,242,699.19 in the previous year[79]. - The company has accumulated a total of 48 patents, including one newly authorized invention patent during the reporting period, demonstrating its commitment to innovation[68]. - The company is actively expanding its market presence by collaborating with various research institutions and universities to enhance its research capabilities in collagen and hollow capsules[67]. - The company is focusing on technology innovation and product upgrades to improve competitiveness in response to market demands[66]. Market Trends and Opportunities - The pharmaceutical auxiliary materials market is expected to grow, driven by the transition to high-quality development in the pharmaceutical industry, with an annual growth rate of over 8% projected during the 14th Five-Year Plan[34]. - The global health supplement market reached $170 billion in 2021, with the U.S. accounting for 31.48% and China growing at a CAGR of 6.6% from 2021 to 2026[37]. - China's health supplement market size was ¥328.9 billion in 2021, with a CAGR of 9.45% from 2011 to 2021, indicating significant growth potential due to lower per capita consumption compared to developed countries[37]. - The functional food market in China achieved a CAGR of 17.78% from 2012 to 2019, reaching ¥358.58 billion in 2019, with substantial room for market penetration[37]. - The company is positioned to benefit from the increasing concentration in the biomedicine and health food sectors, capturing more market share in both B2B and B2C segments[42]. - The collagen peptide market is expected to see rapid growth, particularly in applications related to skin, joints, and bone health, presenting new opportunities for the company[37]. Risk Management - The management highlighted risks related to raw material price fluctuations and regulatory changes in the industry[4]. - The company is implementing measures to mitigate raw material price fluctuation risks, including strategic reserves and diversified supplier management[120]. - Regulatory risks are increasing in the healthcare and nutrition sectors, prompting the company to strengthen its market and policy research efforts[124]. - The company faces intensified market competition, necessitating continuous innovation and improvement in product quality and service capabilities[119]. Corporate Governance and Social Responsibility - The company has established an environmental protection management committee and is compliant with national pollution discharge standards[138]. - The company actively engages in social responsibility and has participated in various charitable activities, including donations for natural disasters and establishing a charity fund for joint care[142]. - The company emphasizes employee rights protection and has implemented an employee stock ownership plan to enhance cohesion and promote mutual growth[141]. - The company has received multiple honors for its corporate culture and employee welfare initiatives, including recognition as a civilized unit in Inner Mongolia[142]. Shareholder Information - The employee stock ownership plan includes 99 employees holding a total of 16,248,404 shares, representing 2.74% of the company's total equity[134]. - The chairman holds 5,042,608 shares, accounting for 0.850% of the company's total equity[134]. - The company approved a cash dividend of RMB 0.26 per 10 shares, totaling RMB 15,433,677.55, distributed to shareholders in May 2023[167]. - The company issued 4,550,000 convertible bonds at a face value of RMB 100 each, raising a total of RMB 455 million, with a net amount of RMB 442,263,443.42 after expenses[168].

包头东宝生物技术股份有限公司 第八届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 | | | 证券代码：300239 证券简称：东宝生物 公告编号：2023-073 4、会议列席人员：公司监事会主席周兴先生以通讯方式列席了本次会议， 监事于建华先生、监事杜学文先生、副总经理贾利明先生、副总经理王刚先生、 财务总监郝海青先生、副总经理兼董事会秘书单华夷女士列席了现场会议。 5、本次会议由董事长王爱国先生主持。 6、本次会议的召集、召开和表决程序符合法律、行政法规、部门规章、规 范性文件和公司《董事会议事规则》、《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 与会董事认真审阅了有关议案并进行了表决。经与会董事一致同意，形成决 议如下： 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届董事会第十六次 会议通知于 2023 年 8 月 18 日以直接送达或电子邮件等方式通知了全体董事、监 事、高级管理人员。 2、会议召开时间、地点及方式：会议于 2023 年 8 月 28 日(星期一)上午 10 ...